Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab


  • Zeng B. Zhu
  • Bruce F. Smith
  • Gene P. Siegal
  • David T. Curiel
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_6197-3



Virotherapy utilizes oncolytic viruses, which may occur naturally or more commonly be engineered, such as conditionally replicative adenoviruses (CRAds), to selectively infect tumor cells and replicate within them, thus causing their demise while sparing surrounding normal cells in the host. Origins of replication result from the replicative life cycle of the virus, which lyses infected tumor cells and releases viral progeny for propagation of infection and resultant lysis of neighboring cancer cells whereby normal host cells are spared.


Virotherapy represents an exciting and novel interventional strategy for a range of neoplastic disorders. In this strategy a virus is rendered conditionally replicative for tumor cells whereby direct oncolytic target killing is achieved. A variety of viral species have been adapted as virotherapy agents with the majority of human clinical trials exploiting conditionally replicative herpes...


Oncolytic Virus Secretory Leukocyte Protease Inhibitor Oncolytic Virotherapy Replicative Adenovirus Primary Ovarian Cancer Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.


  1. Dmitriev I, Kransuyky V, Miller CR et al (1998) An adenovirus vector with genetically modified fibres demonstrates expanded tropism via utilization of a coxsackie virus and adenovirus receptor-independent cell entry mechanism. J Virol 72:9706–9713PubMedPubMedCentralGoogle Scholar
  2. Heise C, Sampson-Johannes A, Williams A et al (1997) ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 3:639–645CrossRefPubMedGoogle Scholar
  3. Kruyt FA, Curiel DT (2002) Toward a new generation of conditionally replicating adenoviruses: pairing tumor selectivity with maximal oncolysis. Hum Gene Ther 13:485–495CrossRefPubMedGoogle Scholar
  4. Stojdl DF, Lichty B, Knowles S et al (2000) Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 6:821–825CrossRefPubMedGoogle Scholar
  5. Yu DC, Chen Y, Dilley J et al (2001) Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res 61:517–525PubMedGoogle Scholar
  6. Zhu ZB, Makhija SK, LU B et al (2004) Transport across a polarized monolayer of caco-2 cells by transferrin receptor-mediated adenovirus transcytosis. Virology 325:116–128CrossRefPubMedGoogle Scholar

See Also

  1. (2012) G2/M checkpoint. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 1481. doi:10.1007/978-3-642-16483-5_2466Google Scholar
  2. (2012) Herpes simplex virus. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 1684. doi:10.1007/978-3-642-16483-5_2688Google Scholar
  3. (2012) Origin of replication. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 2655. doi:10.1007/978-3-642-16483-5_4255Google Scholar
  4. (2012) RGD. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 3297. doi:10.1007/978-3-642-16483-5_5090Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Zeng B. Zhu
    • 1
  • Bruce F. Smith
    • 2
  • Gene P. Siegal
    • 3
  • David T. Curiel
    • 4
  1. 1.Departments of Medicine, Pathology, Surgery, Obstetrics and Gynecology and the Gene Therapy Center, Division of Human Gene TherapyUniversity of Alabama at BirminghamBirminghamUSA
  2. 2.Scott-Ritchey Research Center, College of Veterinary MedicineAuburn UniversityAuburnUSA
  3. 3.Department of PathologyUniversity of Alabama at BirminghamBirminghamUSA
  4. 4.Division of Cancer BiologyWashington UniversitySt. LouisUSA